A.P. Pharma Receives FDA Complete Response Letter

New Post Public Reply Private Reply Replies (0) Message Board
junewong

A.P. Pharma Receives FDA Complete Response Letter for APF530

AP Pharma (OTCBB:APPA)
Intraday Stock Chart

Today : Thursday 28 March 2013

Click Here for more AP Pharma Charts.

A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). The CRL describes the following issues that must be addressed.

  • With respect to chemistry, manufacturing and controls (CMC), the FDA has requested the refinement of one product quality analytical test method, and that certain deficiencies identified during facility pre-approval inspections be addressed.
  • The FDA has requested that a human factors validation study evaluating the usability of the APF530 syringe system together with its proposed product labeling and instructions for use be conducted with product assembled using a validated, commercial process.
  • With respect to clinical, the FDA has requested a re-analysis of the existing Phase 3 clinical data that reclassifies patients into those receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC) according to the recently modified ASCO 2011 Guideline. The FDA did not request any new clinical studies.

“We appreciate the FDA’s thorough review of the APF530 NDA,” stated John B. Whelan, A.P. Pharma’s president and chief executive officer. “While disappointed in today’s notification, we believe that the issues raised in the CRL are addressable, and we remain firmly committed to the successful development of APF530, which we believe will fulfill an important unmet need and improve the lives of patients suffering from CINV. In order to allow us time to carefully address the issues raised in the CRL, we are now projecting product launch for the first half of 2014, versus our prior guidance of the second half of 2013.”

Conference Call Details

A.P. Pharma will host a conference call on Thursday, March 28, 2013 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Interested investors may participate in the conference call by dialing (877) 856-1964 (domestic) or (719) 386-0001 (international) and use participant code 135738. In addition, the live conference call is being webcast and can be accessed on the "Calendar of Events" page of the "Investors" section of the Company's website at  www.appharma.com . A replay of the webcast will be posted to this same section of the website available approximately two hours after the call.

About APF530

A.P. Pharma's lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s proprietary Biochronomer™ drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company’s lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. A.P. Pharma resubmitted its New Drug Application (NDA) for APF530 to the U.S. Food and Drug Administration (FDA) in September 2012 and received a Complete Response Letter in March 2013. For further information, please visit the Company's web site at  www.appharma.com .

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with the potential approval of APF530 and the potential timing for such approval, if approved at all, the projected timing for the commercial launch of APF530, if approved, as well as risks relating to capital resources and liquidity, satisfactory completion of clinical studies, progress in research and development programs, successful launch and acceptance of new products and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cala Launches Game-Changer Wearable for Tremor Relief

Updated Category News Views 7

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Continue Reading
JiMMYBAR! Expands Creatine Market with Target Launch

Updated Category News Views 4

JiMMYBAR! Breaks New Ground in Supplements You ever notice how some companies just know how to shake things up? Take JiMMYBAR!, for instance. The moment I read they’re making moves to get their Creatine + Protein bars into Target stores nationwide, starting October 4, I thought, “That’s one way to drag creatine out from the dusty tub and onto the shelves of...

Continue Reading
Navigating Holiday Sweets: Healthy Balancing Acts

Updated Category News Views 1

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Continue Reading
Bob Evans' Protein Mac & Cheese: Practical Power Play

Updated Category News Views 10

Has anyone else noticed just how fast the world spins when it comes to consumer trends these days? Bob Evans is hopping right on the protein bandwagon with its latest launch, a microwave-ready Protein Macaroni & Cheese that packs 18 grams of protein per serving. You gotta hand it to them for seizing opportunity when they see it. This one's not just about tossing a new...

Continue Reading
Community Banks Missing $106B Lending Opportunity?

Updated Category News Views 3

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Continue Reading
IWP and VYRE Unveil 'The Plug' for VBNGtv Content

Updated Category News Views 4

Bringing Capital and Content Under One Roof There's something in the air as Itibari-Waynne & Partners (IWP) team up with the VYRE Network to crank out a fresh slate of content for VYRE Business News Global (VBNGtv). This partnership ain't just another splash in the buzzy world of digital media; it's like merging Wall Street with Hollywood. IWP, prepping to go full...

Continue Reading
Cure Blindness Project's 770K Screenings for World Sight Day

Updated Category News Views 5

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Continue Reading
Pushing for National Liver Cancer Awareness in 2026

Updated Category News Views 3

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

Continue Reading
Purina Institute Highlights Nutritional Science at WSAVA 2026

Updated Category News Views 6

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Continue Reading
TA Services Strengthens U.S.-Mexico Freight Operations

Updated Category News Views 3

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Continue Reading

Top 5 Most Recently Viewed Articles

Giga Metals Corporation's Upcoming Presentation at Key Conference

Updated Category News Views 86

Introduction to Giga Metals Corporation Giga Metals Corporation (TSXV: GIGA, OTCQX: GIGGF) is a budding junior mining company dedicated to exploring and developing vital resources like nickel and cobalt. These materials play a crucial role in various sectors, including electric vehicles and energy storage systems. The company's flagship asset, the Turnagain Project, is an...

Continue Reading
Discover 'Project Aura': XREAL's Newest XR Device Launch

Updated Category News Views 456

XREAL's Exciting Launch of Project Aura XREAL has taken a monumental step forward in the world of augmented reality by announcing Project Aura, during a recent developer conference. This innovative optical see-through XR device is developed specifically for the Android XR platform through a groundbreaking partnership with Google. The collaboration aims to revolutionize...

Continue Reading
Birmingham City and Delta Air Lines Team Up for New Season

Updated Category News Views 146

Birmingham City Football Club Teams Up with Delta Air Lines Birmingham City Football Club has revealed that Delta Air Lines will be its Official Airline Partner for the upcoming 2024-2025 season. This remarkable partnership highlights how appealing the club has become to prestigious global brands, illustrating the potential for shared storytelling and branding efforts....

Continue Reading
Loews Corporation Achieves Favorable Court Ruling on Pipeline Case

Updated Category News Views 183

Loews Corporation Celebrates Legal Victory Loews Corporation (NYSE: L) has recently marked a significant legal win regarding its acquisition of Boardwalk Pipelines. This important milestone comes after a ruling from the Delaware Court of Chancery, which determined that there was no liability associated with the company’s 2018 purchase of minority limited partner...

Continue Reading
Neuberger Berman Fund Announces Exciting Monthly Payout

Updated Category News Views 167

Neuberger Berman High Yield Strategies Fund Declares Monthly Distribution Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) has officially announced an upcoming distribution declaration of $0.0905 per share of its common stock. This regular distribution is part of its commitment to providing consistent returns for shareholders. Details on the Monthly...

Continue Reading